Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Inovio Pharmaceuticals stock | $6.84

Learn how to easily invest in Inovio Pharmaceuticals stock.

Inovio Pharmaceuticals Inc is a biotechnology business based in the US. Inovio Pharmaceuticals shares (INO) are listed on the NASDAQ and all prices are listed in US Dollars. Inovio Pharmaceuticals employs 262 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Inovio Pharmaceuticals

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – INO – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Inovio Pharmaceuticals stock price (NASDAQ: INO)

Use our graph to track the performance of INO stocks over time.

Inovio Pharmaceuticals shares at a glance

Information last updated 2021-10-23.
Latest market close$6.84
52-week range$5.81 - $19.00
50-day moving average $7.38
200-day moving average $8.01
Wall St. target price$13.22
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.75

Buy Inovio Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
N/A
$20 per year
N/A
Financial advice powered by relationships, not commissions.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Moomoo
Stocks
$0
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Inovio Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Inovio Pharmaceuticals price performance over time

Historical closes compared with the close of $6.84 from 2021-10-26

1 week (2021-10-20) -2.84%
1 month (2021-09-27) -11.97%
3 months (2021-07-27) -17.19%
6 months (2021-04-27) -4.60%
1 year (2020-10-27) -38.43%
2 years (2019-10-25) 188.61%
3 years (2018-10-26) 35.71%
5 years (2016-10-27) 6.71%

Inovio Pharmaceuticals financials

Revenue TTM $6.5 million
Gross profit TTM $-86,834,216
Return on assets TTM -24.33%
Return on equity TTM -40.79%
Profit margin 0%
Book value $2.42
Market capitalisation $1.4 billion

TTM: trailing 12 months

Shorting Inovio Pharmaceuticals shares

There are currently 45.2 million Inovio Pharmaceuticals shares held short by investors – that's known as Inovio Pharmaceuticals's "short interest". This figure is 1.7% up from 44.5 million last month.

There are a few different ways that this level of interest in shorting Inovio Pharmaceuticals shares can be evaluated.

Inovio Pharmaceuticals's "short interest ratio" (SIR)

Inovio Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Inovio Pharmaceuticals shares currently shorted divided by the average quantity of Inovio Pharmaceuticals shares traded daily (recently around 3.7 million). Inovio Pharmaceuticals's SIR currently stands at 12.06. In other words for every 100,000 Inovio Pharmaceuticals shares traded daily on the market, roughly 12060 shares are currently held short.

However Inovio Pharmaceuticals's short interest can also be evaluated against the total number of Inovio Pharmaceuticals shares, or, against the total number of tradable Inovio Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Inovio Pharmaceuticals's short interest could be expressed as 0.21% of the outstanding shares (for every 100,000 Inovio Pharmaceuticals shares in existence, roughly 210 shares are currently held short) or 0.2185% of the tradable shares (for every 100,000 tradable Inovio Pharmaceuticals shares, roughly 219 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Inovio Pharmaceuticals.

Find out more about how you can short Inovio Pharmaceuticals stock.

Inovio Pharmaceuticals share dividends

We're not expecting Inovio Pharmaceuticals to pay a dividend over the next 12 months.

Have Inovio Pharmaceuticals's shares ever split?

Inovio Pharmaceuticals's shares were split on a 1:4 basis on 5 June 2014. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Inovio Pharmaceuticals shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Inovio Pharmaceuticals shares which in turn could have impacted Inovio Pharmaceuticals's share price.

Inovio Pharmaceuticals share price volatility

Over the last 12 months, Inovio Pharmaceuticals's shares have ranged in value from as little as $5.81 up to $19. A popular way to gauge a stock's volatility is its "beta".

INO.US volatility(beta: 0.7)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Inovio Pharmaceuticals's is 0.7048. This would suggest that Inovio Pharmaceuticals's shares are less volatile than average (for this exchange).

Inovio Pharmaceuticals overview

Inovio Pharmaceuticals, Inc. , a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon optimized plasmids that have ability to help break the immune system's tolerance of cancerous or infected cells and facilitate cross-strain protection against unmatched and matched pathogen variants. The company is involved in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus). Its partners and collaborators include ApolloBio Corp. , AstraZeneca, Beijing Advaccine Biotechnology Co. , Ltd.

Frequently asked questions

What percentage of Inovio Pharmaceuticals is owned by insiders or institutions?
Currently 1.656% of Inovio Pharmaceuticals shares are held by insiders and 35.965% by institutions.
How many people work for Inovio Pharmaceuticals?
Latest data suggests 262 work at Inovio Pharmaceuticals.
When does the fiscal year end for Inovio Pharmaceuticals?
Inovio Pharmaceuticals's fiscal year ends in December.
Where is Inovio Pharmaceuticals based?
Inovio Pharmaceuticals's address is: 660 West Germantown Pike, Plymouth Meeting, PA, United States, 19462
What is Inovio Pharmaceuticals's ISIN number?
Inovio Pharmaceuticals's international securities identification number is: US45773H2013
What is Inovio Pharmaceuticals's CUSIP number?
Inovio Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 371916107

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site